Acer Inc. was founded in 1976 by Stan Shih and is a Taiwan-based global technology company with operations in over 160 countries. Building on its strong foundation in computing and data technologies, Acer has strategically expanded into the biomedical field to develop a next-generation RNA therapeutics platform. Since 2018, the company has focused on personalized cancer vaccines, powered by proprietary AI models for high-precision neoantigen prediction. This AI-driven engine enables rapid identification of clinically relevant targets, significantly accelerating and improving the design of individualized immunotherapies. In 2021, Acer established its mRNA-LNP platform and has since developed a proprietary ionizable lipid, AIL-111, engineered for high delivery efficiency and favorable in vivo performance. This platform enables robust mRNA delivery and serves as the foundation for multiple therapeutic applications. Leveraging this core capability, Acer is advancing a targeted LNP (tLNP) platform for cell-specific delivery, including in vivo CAR-T cell generation, where mRNA is directly delivered to T cells within the body to induce transient CAR expression. This approach has the potential to simplify manufacturing, reduce cost, and improve accessibility compared to conventional ex vivo cell therapies. By integrating AI-driven antigen discovery, proprietary LNP delivery technology, and in vivo cell engineering, Acer is building a scalable and modular platform for next-generation RNA medicines. The company aims to become a key innovator at the intersection of digital technology and biopharmaceutical development, enabling transformative therapies for cancer and beyond.
Abzena
Abzena is a bioconjugate- and biologics-focused CDMO that pushes development of novel treatments forward at every stage from discovery through commercial launch. With the ability to tailor its strategy and customer experience to each project, Abzena develops and implements innovative solutions that enable biotech and biopharma companies to realize the full potential of their investments in human health. The company has research, development, and cGMP facilities across locations in San Diego, CA, Bristol, PA, and Cambridge, UK. #bioconjugation #linkerpayloads #ADCs #Biologics # | Abzena is the leading end-to-end bioconjugate and complex biologics CDMO + CRO. From discovery through commercial launch, we support customers with fully integrated programs or individual services designed to de-risk and streamline the development of new treatments for patients in need. With the ability to tailor its strategy and customer experience to each project, Abzena develops and implements innovative solutions that enable biotech and biopharma companies to realize the full potential of their molecule and move medicines forward faster. The company has research, development, and cGMP facilities across locations in San Diego, CA, Bristol, PA, and Cambridge, UK. We provide comprehensive support for multiple modalities including: Antibodies (mAbs), FAbs, ADCs, Bispecifics, Radioconjugates, Fusion Proteins, Growth Factors, Vaccines, mRNA, Biosimilars, Peptide Oligonucleotides. Our capabilities range from: Early-Stage Research & Discovery, Design and Lead Selection, Robust Analytics, Bioassays and Immunogenicity, Antibody Engineering and Developability, Mammalian Cell Line Development, Linker Payload Design and Synthesis, Analytical Method & Formulation Development, Process Development and cGMP Manufacturing up to 2000L, Technology Transfer & Scale-Up, Regulatory Support Our extensive toolkit of services is designed to ensure our customers achieve their Target Product Profile (TPP). With early-stage research, process development and GMP manufacturing capabilities all under a single organization, we can leverage our vast capabilities and knowledge of the product, along with the requisite In Vitro and In Vivo criteria to ensure that the desired TPP can be accomplished from the project outset. | Abzena is the leading end-to-end bioconjugate (ADCs, AOCs, RDCs) and complex biologics CDMO + CRO. From discovery through commercial, we support customers with fully integrated programs or individual services that de-risk and streamline the development of new medicines. With over two decades of experience, 2000+ conjugates developed and over 200+ cell lines developed, we have the expertise and technical know-how to rapidly progress your biopharmaceutical to IND and beyond. And with footholds in the US and UK, we offer a simplified and secure supply chain. Fully integrated CDMO+CRO support across multiple modalities: Monoclonal Antibodies (mAbs), Antibody-Drug Conjugates (ADCs), Antibody-Oligonucleotide Conjugates (AOCs), Radionuclide Antibody-Conjugates (RACs) & Radionuclide Drug-Conjugates (RDCs),Bispecific Antibodies (bsAbs), Fusion Proteins, Cytokines, Recombinant & Conjugate Vaccines, Nanoparticles With Capabilities Ranging From: Early-Stage Research & Discovery, Design and Lead Selection, Robust Analytics, Bioassays and Immunogenicity, Bioconjugation & Chemistry, Antibody, Engineering and Developability, Mammalian Cell Line Development, Linker Payload Design and Synthesis, Analytical Method & Formulation Development, Process Development and cGMP Manufacturing up to 2000L, Technology Transfer & Scale-Up, Regulatory Support. Key Facts & Highlights: Over 24 years of experience developing 2000+ conjugations and 200+ cell lines. Champion Award Winner in Global Biologics at the 2025 CDMO Leadership Awards. Unique end-to-end value proposition ranging from antibody discovery to clinical-scale GMP biologic drug substance manufacture. Scientific expertise to deliver at high quality, low cost and compressed timelines. Global customer base, including most of the top 20 biopharmaceutical companies. Supply chain security with fully integrated US & UK facilities that can handle highly potent and cytotoxic molecules. 14 products utilizing Abzena’s technologies in clinical trials. Biologics discovery, design, optimization, characterization, lead selection, cell line development, process development & GMP manufacture for supply from preclinical through commercial scale. Bioconjugate (including ADCs, AOCs, RDCs) discovery, design, optimization, characterization, lead selection, cell line development, process development & GMP manufacture for supply from preclinical through commercial scale. Synthesis, analysis and GMP manufacture of APIs, payloads and highly potent compounds (HPAPI) and cytotoxic. Discovery to Phase II accelerated development for antibody-drug conjugates, including antibodies, linkers, and payloads. Tech transfer and commercial scale manufacturing up to 2000L for biologics and bioconjugates.
3PBIOVIAN
3PBIOVIAN is a globally operating Contract Development and Manufacturing Organization (CDMO), delivering end-to-end services for biotech and pharma companies. Our service offering includes microbial and mammalian protein expression platforms, viral vector production for adenoviruses and adeno-associated viruses, cell therapy, and plasmid DNA production. Additionally, we provide fill and finish services for recombinant proteins and viral vectors. With a combined track record of 40 years in process development and analytical methods development, complemented by our experience in process scale-up, GMP manufacturing, and commercial supply, we are equipped to offer comprehensive manufacturing services at all stages, encompassing Drug Substance and Drug Product. Our manufacturing sites in Pamplona-Noáin, Spain, and Turku, Finland seamlessly support the diverse needs of our clients, covering pre-clinical and clinical supply to full-scale commercial manufacturing. | 3PBIOVIAN is a globally operating Contract Development and Manufacturing Organisation (CDMO), providing unparalleled end-to-end development and manufacturing services for biologics and advanced therapies. Collaboration is at the core of how we work. We partner closely with our clients, adapting to their unique needs and guiding them through every stage: from clinical development and trials to commercial production. Our client-oriented approach ensures seamless project execution and efficient progression. Our service offering spans multiple platforms, including microbial and mammalian expression systems, adenoviruses, adeno-associated viruses (AAV), cell therapy, and plasmids. With a diverse range of bioreactor sizes, we offer flexible production scaling to meet the needs of biopharmaceutical companies worldwide. Leveraging decades of expertise and extensive capabilities, we position ourselves as a leading pan-European independent biologics CDMO, dedicated to advancing therapies that address patients’ unmet clinical needs, making advanced biologics and tomorrow’s life transforming therapies. GMP certified 3PBIOVIAN offers GMP manufacturing services for microbial and mammalian protein expression platforms, viral vector production for adenoviruses and AAVs, cell therapy, and plasmid DNA production. Summary of services › Plasmid DNA production › Cell line development › GMP cell banking and Virus Seed Stock production › Process development and optimisation › Technology transfer › Analytical methods development, qualification, and validation › Scale-up and cGMP manufacturing › Formulation development › Fill and Finish › Quality Assurance (QA) and Quality Control (QC) › Drug Substance (DS) & Drug Product (DP) release GMP manufacturing capacities › Mammalian, single use bioreactors: 50L, 200L, 400L, 2000L › Microbial, stainless-steel bioreactors: 10L, 100L, 200L, 500L, 1000L › Viral Vector manufacturing: • Adherent: Up to 500 m2 • Suspension: 10L, 25L, 50L, 200L › Plasmid DNA, stainless steel bioreactors: 25L, 40L, 200L